ASP Isotopes 2025 Q3 Earnings Net Loss Widens 75.3% Amid Revenue Surge

ASP Isotopes (ASPI) reported fiscal 2025 Q3 earnings on Nov 19, 2025, with revenue surging 349.5% year-over-year but losses widening. The results fell short of profitability, underscoring ongoing financial challenges.

Revenue

Total revenue surged to $4.89 million in Q3 2025, a 349.5% increase from $1.09 million in Q3 2024. This growth was driven by a 3,620% expansion in construction services revenue to $3.62 million, while specialist isotopes and related services contributed $1.27 million. Notably, the nuclear fuels segment reported $0 in revenue, indicating a strategic shift or operational pause in that line.

Earnings/Net Income

ASP Isotopes’s losses deepened significantly, with a net loss of $12.89 million in Q3 2025—75.3% wider than the $7.36 million loss in Q3 2024. Earnings per share (EPS) declined to -$0.15 from -$0.12, reflecting persistent financial strain. The company has now posted losses in three consecutive years for the same quarter, signaling unresolved operational challenges.

Price Action

The stock price of ASP Isotopes has faced steep declines, dropping 3.10% in a single trading day, 15.45% over the past week, and 26.90% month-to-date as of Nov 19, 2025.

Post-Earnings Price Action Review

Historically, buying ASP Isotopes shares the day after earnings releases and holding for 30 days has yielded strong returns. Over the past three years, the average total shareholder return was 22.8%, peaking at 27.5% in 2023 and hitting a low of 18.1% in 2024. This strategy appears to capitalize on investor optimism post-earnings, despite the company’s current financial struggles.

Additional News

Recent insider activity highlights CEO Robert Ainscow’s transactions. On Nov 17, 2025, Ainscow surrendered 67,500 shares via a prearranged trading plan to cover tax liabilities, valued at $7.51 per share. Separately, he filed to sell 25,000 restricted shares through Independent Trading Group (ITG) Inc., with an approximate sale date of Nov 25. These moves, executed under SEC Rule 10b5-1, underscore executive liquidity needs amid the company’s ongoing losses.